-
Leap Therapeutics NASDAQ:LPTX Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Location: 47 Thorndike St Ste B1-1, Massachusetts, 02141-1799, US | Website: www.leaptx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
38.33M
Cash
78.48M
Avg Qtr Burn
-12.51M
Short % of Float
3.38%
Insider Ownership
14.13%
Institutional Own.
40.28%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DKN-01 (+/- Paclitaxel) Details Cancer, Carcinosarcoma, Ovarian cancer, Endometrial cancer | Phase 3 Update | |
DKN-01 (Bevacizumab & Chemotherapy) Details Cancer, Colorectal cancer | Phase 2 Data readout | |
DKN-01 + pembrolizumab Details Endometrial cancer, Cancer | Phase 2 Data readout | |
DKN-01 (+ tislelizumab +/- CAPOX) Details Gastroesophageal junction tumors, Cancer, Gastric cancer | Phase 2a Data readout | |
FL-301 Details Cancer, Pancreatic cancer, Gastric cancer | Phase 1 Data readout | |
DKN-01 monotherapy or in combination with docetaxel Details Prostate cancer | Failed Discontinued |